All 28 patients have been selected for an early-stage clinical trial of a stem cell therapy to treat retinitis pigmentosa – and initial results have proved promising, the company behind the treatment says.
Eight patients have now received the intravitreal injection of stem cells, intended as a rescue mechanism for the dying retinal cells and a potential source of new photoreceptors, and have been followed for one year.
The one-off procedure can be performed in an ophthalmologist’s office, using local anaesthesia.
Regenerative medicine company jCyte has announced that, based on the “exciting” results of this Phase I/IIa trial, it hopes to launch the Phase IIb trial next year.
A jCyte spokesman told OT that the Phase I/IIa trial, which has been conducted in California, focused on safety, adding: “The next trial, Phase IIb, will look at efficacy.”
In a statement from the company, jCyte co-founder, Dr Henry Klassen, highlighted that: “So far, trial participants have had no significant side effects, with good tolerance of the injected cells. We are quite gratified by the results."